Sana Biotechnology has closed its first round with more than $700m after investors including GV swung behind its vision to commercialise cell therapies.
Sana Biotechnology, a US-based developer of stem cell medicines based on research at multiple universities, closed its inaugural funding round at $700m on Tuesday with commitments from investors including conglomerate Alphabet.
F-Prime Capital, a unit of financial services group Fidelity, also took part in the round, as did Arch Venture Partners, Flagship Pioneering, Canada Pension Plan Investment Board, Baillie Gifford, Alaska Permanent Fund and the Public Sector Pension Investment Board.
Bezos Expeditions, Omega Funds, Altitude Life Science Ventures and…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
